Description
SIRTURO (BEDAQUILINE) 100MG TAB 188CT
First action · last action
2023-03-01 · 2023-03-01
Transactions
1
First transaction's obligation
$22,685
Base + all options value (sum of deltas)
$22,685
Extent competed
NOT COMPETED UNDER SAP
Other than full & open authority
SAP NON-COMPETITION (FAR 13)
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2023-03-01+$22,685= $22,685
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2023-03-01 | +$22,685 | $22,685 | SIRTURO (BEDAQUILINE) 100MG TAB 188CT |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI U7XLCG7L2LC5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24226P0887 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $19,215 | FY2026 |
| 36C24226P0878 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $15,609 | FY2026 |
| 36C24526P0520 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $19,215 | FY2026 |
| 36C24226P0738 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $19,215 | FY2026 |
| 36C24526P0488 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $19,215 | FY2026 |
| 36C24226P0662 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $19,215 | FY2026 |
Other recipients under 6505 from 261-NETWORK CONTRACT OFFICE 21 (36C261) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26126P1178 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
| 36C26126P1102 | ENVIGO RMS LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $74,586 | FY2026 |
| 36C26126P0961 | 10X GENOMICS, INC. | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $34,600 | FY2026 |
| 36C26126P0997 | SIERRA RADIOPHARMACY LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $247,204 | FY2026 |
| 36C26126P1008 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26123P0733_3600_-NONE-_-NONE- · retrieved 2026-09-26.